Bristol Myers Squibb: Deep Value Play or Patent Cliff Trap?

Bristol Myers Squibb (BMY) is currently trading at valuation levels that suggest a significant discount compared to the broader pharmaceutical sector. With a forward price-to-earnings ratio of 9.4—well below the healthcare sector average of 17.3—and a price-to-sales ratio of 2.5, the company appears to be a bargain for value-oriented investors. However, these low multiples are largely a reflection of a looming 'patent cliff.' The company's two top-selling drugs, the blood thinner Eliquis and the cancer immunotherapy Opdivo, are both set to lose patent protection in 2028. Together, these two blockbusters account for nearly half of the company's total revenue, creating a substantial headwind for future growth. To mitigate these losses, BMY is leaning on a growth portfolio including Opdualag, Sotyktu, and Camzyos. While sales from these newer products rose 17% year-over-year in 2025, legacy drugs still represent approximately 45% of total revenue. The company expects a slight revenue decrease this year compared to 2025. Despite the growth concerns, the stock remains a compelling option for income investors. BMY offers a forward dividend yield of 4.3% and has maintained a record of increasing dividends for 17 consecutive years. While other peers like Pfizer may offer even lower P/E multiples, BMY's combination of yield and discounted cash flow potential—with some models suggesting a 40% upside—keeps it in the conversation for value portfolios.